Product Details
Molecular Formula
C19H18ClN3O5S
Grade
Pharmaceutical grade
Description
Rivaroxaban is an orally active active pharmaceutical ingredient (API) classified as a direct, selective, and reversible inhibitor of Factor Xa (FXa) in the coagulation cascade. By binding directly to the active site of FXa, it inhibits both free and prothrombinase-bound FXa, thereby reducing thrombin generation and preventing thrombus formation without requiring cofactors such as antithrombin III.
Stability and Storage Conditions
Air Sensitive
Solubility
Insoluble in H2O; insoluble in EtOH; ≥13.9 mg/mL in DMSO with gentle warming
Storage
Inert atmosphere,2-8°C
Applications
The Rivaroxaban API is used in the manufacture of film-coated tablets for the prevention and treatment of thromboembolic disorders. Its key clinical applications include: prevention of venous thromboembolism (VTE) in patients undergoing elective hip or knee replacement surgery; treatment and secondary prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE); stroke and systemic embolism prevention in patients with non-valvular atrial fibrillation; and, in combination with antiplatelet therapy, for the prevention of atherothrombotic events in patients with coronary artery disease or peripheral artery disease.
SMILES
C1(C(NC[C@@H]2OC(=O)N(C3=CC=C(N4CCOCC4=O)C=C3)C2)=O)SC(Cl)=CC=1
InChI
InChI=1S/C19H18ClN3O5S/c20-16-6-5-15(29-16)18(25)21-9-14-10-23(19(26)28-14)13-3-1-12(2-4-13)22-7-8-27-11-17(22)24/h1-6,14H,7-11H2,(H,21,25)/t14-/m0/s1
Water Solubility
Insoluble in H2O
InChI Key
KGFYHTZWPPHNLQ-AWEZNQCLSA-N
Toxicity
366789-02-8(Hazardous Substances Data)